{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:04:45Z","timestamp":1792652685796,"version":"4.5.0"},"reference-count":90,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Recently, metabolic associated steatotic liver disease (MASLD) became the leading cause of chronic liver disease worldwide and one of the most frequent causes of hepatocellular carcinoma (HCC). Nonetheless, in this epidemiological trend, viral hepatitis remains the major driver in hepatic carcinogenesis. Globally, hepatitis B virus (HBV) is the leading cause of hepatocellular carcinoma, with an overall attributable risk of approximately 40%, followed by hepatitis C virus (HCV), which accounts for 28\u201330% of cases, with significant geographic variations between the Eastern and Western world. Considering all the etiologies, HCC risk increases proportionally with the progression of liver disease, but the risk is consistently higher in patients with viral triggers. This evidence indicates that both direct (due to the oncogenic properties of the viruses) and indirect (through the mechanisms of chronic inflammation that lead to cirrhosis) mechanisms are involved, alongside the presence of co-factors contributing to liver damage (smoking, alcohol, and metabolic factors) that synergistically enhance the oncogenic process. The aim of this review is to analyze the oncogenic role of hepatitis viruses in the liver, evaluating epidemiological changes and direct and indirect viral mechanisms that lead to liver cancer.<\/jats:p>","DOI":"10.3390\/cancers16081505","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T08:08:12Z","timestamp":1713168492000},"page":"1505","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The Role of Hepatitis Viruses as Drivers of Hepatocancerogenesis"],"prefix":"10.3390","volume":"16","author":[{"given":"Mario","family":"Capasso","sequence":"first","affiliation":[{"name":"Diseases of the Liver and Biliary System Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Cossiga","sequence":"additional","affiliation":[{"name":"Diseases of the Liver and Biliary System Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0460-4122","authenticated-orcid":false,"given":"Maria","family":"Guarino","sequence":"additional","affiliation":[{"name":"Diseases of the Liver and Biliary System Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Ranieri","sequence":"additional","affiliation":[{"name":"Diseases of the Liver and Biliary System Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filomena","family":"Morisco","sequence":"additional","affiliation":[{"name":"Diseases of the Liver and Biliary System Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.cgh.2023.04.015","article-title":"The Global Burden of Liver Disease","volume":"21","author":"Younossi","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: Trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Net. Rev. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/MCG.0b013e3182872f29","article-title":"Epidemiology of hepatocellular carcinoma: Consider the population","volume":"47","author":"Mittal","year":"2013","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jhep.2019.08.025","article-title":"Epidemiology and surveillance for hepatocellular carcinoma: New trends","volume":"72","author":"Singal","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/liv.14735","article-title":"on behalf of the ITA.LI.CA study group. The changing scenario of hepatocellular carcinoma in Italy: An update","volume":"41","author":"Garuti","year":"2021","journal-title":"Liver Int."},{"key":"ref_7","unstructured":"(2024, April 13). AIOM. Available online: www.iss.it\/documents\/20126\/8404074\/LG97_AISF-AIOM_Epatocarcinoma."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"686962","DOI":"10.3389\/fonc.2021.686962","article-title":"Risk Factors and Prevention of Viral Hepatitis-related Hepatocellular carcinoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/aje\/155.4.323","article-title":"Alcohol and Hepatocellular Carcinoma: The Effect of Lifetime Intake and Hepatitis Virus Infections in Men and Women","volume":"155","author":"Donato","year":"2002","journal-title":"Am. J. Epidemiol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Stroffolini, T., and Stroffolini, G. (2023). A Historical Overview on the Role of Hepatitis B and C Viruses as Aetiological Factors for Hepatocellular Carcinoma. Cancers, 15.","DOI":"10.3390\/cancers15082388"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jhep.2016.04.031","article-title":"Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study","volume":"65","author":"Vandenbulcke","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/1055-9965.EPI-09-1297","article-title":"Interaction between cigarette smoking and hepatitis B and C virus infection on the risk of liver cancer: A meta-analysis","volume":"19","author":"Chuang","year":"2010","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/ijc.31181","article-title":"Interaction between tobacco smoking and hepatitis B virus infection on the risk of liver cancer in a Chinese population","volume":"142","author":"Liu","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1053\/j.gastro.2017.07.001","article-title":"Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort Study","volume":"153","author":"Yu","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Vetrano, E., Rinaldi, L., Mormone, A., Giorgione, C., Galiero, R., Caturano, A., Nevola, R., Marfella, R., and Sasso, F.C. (2023). Non-alcoholic Fatty Liver Disease, Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020468"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3350\/cmh.2021.0383","article-title":"Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases","volume":"28","author":"Shin","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/dmrr.1291","article-title":"Diabetes mellitus and risk of hepatocellular carcinoma: A systematic review and meta-analysis","volume":"28","author":"Wang","year":"2012","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/ijc.26165","article-title":"Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: A systematic review and meta-analysis of cohort studies","volume":"130","author":"Wang","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1053\/j.gastro.2003.10.065","article-title":"Diabetes Increases the Risk of Chronic Liver Disease and Hepatocellular Carcinoma","volume":"126","author":"Tran","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/CEJ.0000000000000669","article-title":"Associations between diabetes mellitus and the risk of hepatocellular carcinoma in Asian individuals with hepatitis B and C infection: Systematic review and a meta-analysis of cohort studies","volume":"31","author":"Chao","year":"2022","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2147\/CMAR.S188238","article-title":"Type 2 diabetes mellitus increases the risk of hepatocellular carcinoma in subjects with chronic hepatitis B virus infection: A meta-analysis and systematic review","volume":"11","author":"Tan","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s10620-015-3983-3","article-title":"Diabetes Mellitus Increases the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Virus Patients: A Systematic Review","volume":"61","author":"Dyal","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"965548","DOI":"10.3389\/fimmu.2022.965548","article-title":"NAFLD and HBV interplay-related mechanisms underlying liver disease progression","volume":"13","author":"Tourkochristou","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jamaoncol.2018.0035","article-title":"Association of high body mass index and hepatocellular carcinoma in patients with chronic hepatitis B virus infection: A Korean population-based cohort study","volume":"4","author":"Kim","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cgh.2007.02.039","article-title":"Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis","volume":"5","author":"Ioannou","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cgh.2006.05.013","article-title":"Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis","volume":"4","author":"Paries","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4254\/wjh.v11.i1.1","article-title":"Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review","volume":"11","author":"Desai","year":"2019","journal-title":"World J. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular Carcinoma in Cirrhosis: Incidence and Risk Factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13027-016-0099-0","article-title":"Hepatitis C virus genotypes distribution: An epidemiological up-date in Europe","volume":"11","author":"Petruzziello","year":"2016","journal-title":"Infect. Agent. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.21672","article-title":"Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma","volume":"46","author":"Matsuzaki","year":"2007","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"589908","DOI":"10.3389\/fonc.2020.589908","article-title":"Hepatocellular Senescence: Immunosurveillance and Future Senescence-Induced Therapy in Hepatocellular Carcinoma","volume":"10","author":"Liu","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41421-020-00214-5","article-title":"Global immune characterization of HBV\/HCV-related hepatocellular carcinoma identifies macrophage and T-cell subsets associated with disease progression","volume":"6","author":"Song","year":"2020","journal-title":"Cell Discov."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2016.07.009","article-title":"Hepatocarcinogenesis associated with hepatitis B, delta and C viruses","volume":"20","author":"Schwartz","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3892\/or.2016.4775","article-title":"Hepatitis C virus core protein regulates OCT4 expression and promotes cell cycle progression in hepatocellular carcinoma","volume":"36","author":"Zhou","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1038\/onc.2012.484","article-title":"Hepatitis C virus-induced activation of \u03b2-catenin promotes c-Myc expression and a cascade of pro-carcinogenetic events","volume":"32","author":"Higgs","year":"2013","journal-title":"Oncogene"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.3748\/wjg.v26.i38.5759","article-title":"Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma","volume":"26","author":"Lau","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1440-1746.2009.06201.x","article-title":"Hepatitis C virus core protein induces malignant transformation of biliary epithelial cells by activating nuclear factor-kappa B pathway","volume":"25","author":"Li","year":"2010","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"342","DOI":"10.4254\/wjh.v4.i12.342","article-title":"Hepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategies","volume":"4","author":"Selimovic","year":"2012","journal-title":"World J. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"30711","DOI":"10.1074\/jbc.M209623200","article-title":"Hepatitis C virus NS5A protein modulates c-Jun N-terminal kinase through interaction with tumor necrosis factor receptor-associated factor 2","volume":"278","author":"Park","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"Global Burden of Disease Liver Cancer Collaboration. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results from the Global Burden of Disease Study 2015","volume":"3","author":"Akinyemiju","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199306243282501","article-title":"Risk factors for hepatocellular carcinoma among patients with chronic liver disease","volume":"328","author":"Tsukuma","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1002\/1097-0142(19941015)74:8<2234::AID-CNCR2820740805>3.0.CO;2-6","article-title":"Risk of hepatocellular carcinoma in patients with cirrhosis in Japan","volume":"74","author":"Kato","year":"1994","journal-title":"Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Ioannou, G.N., Green, P., Lowy, E., Mun, E.J., and Berry, K. (2018). Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0204412"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2020). EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol., 73, 1170\u20131218.","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"on Behalf of Rete Sicilia Selezione Terapia\u2013HCV (RESIST-HCV) Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated with Direct-Acting Antiviral Agents","volume":"155","author":"Calvaruso","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of Hepatocellular Cancer in HCV Patients Treated with Direct-Acting Antiviral Agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.28535","article-title":"Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection","volume":"64","author":"Kanwal","year":"2016","journal-title":"Hepatology"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Morisco, F., Federico, A., Marignani, M., Cannav\u00f2, M., Pontillo, G., Guarino, M., Dallio, M., Pegini, P., Benigno, R.G., and Lombardo, F.L. (2021). Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study. Cancers, 13.","DOI":"10.3390\/cancers13153810"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.dld.2023.01.153","article-title":"Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort","volume":"55","author":"Kondili","year":"2023","journal-title":"Dig. Liver Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.30823","article-title":"Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated with Direct Acting Antiviral Agents","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/apt.17802","article-title":"Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication","volume":"59","author":"Vutien","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jhep.2016.02.021","article-title":"Mechanisms of HBV-induced hepatocellular carcinoma","volume":"64","author":"Levrero","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/ng.2295","article-title":"Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma","volume":"44","author":"Sung","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Datfar, T., Doulberis, M., Papaefthymiou, A., Hines, I.N., and Manzini, G. (2021). Viral Hepatitis and Hepatocellular Carcinoma: State of the Art. Pathogens, 10.","DOI":"10.3390\/pathogens10111366"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Sivasudhan, E., Blake, N., Lu, Z., Meng, J., and Rong, R. (2022). Hepatitis B Viral Protein HBx and the Molecular Mechanisms Modulating the Hallmarks of Hepatocellular Carcinoma: A Comprehensive Review. Cells, 11.","DOI":"10.3390\/cells11040741"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.dld.2020.10.007","article-title":"HBx acts as an oncogene and promotes the invasion and metastasis of hepatocellular carcinoma both in vivo and vitro","volume":"53","author":"Yang","year":"2021","journal-title":"Dig. Liver Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1515\/BC.2003.022","article-title":"Transcriptional repression of the human p53 gene by hepatitis B viral core protein (HBc) in human liver cells","volume":"384","author":"Kwon","year":"2003","journal-title":"Biol. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1096\/fj.201701144R","article-title":"Hepatitis B virus core protein promotes hepatocarcinogenesis by enhancing Src expression and activating the Src\/PI3K\/Akt pathway","volume":"32","author":"Liu","year":"2018","journal-title":"FASEB J."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol., 67, 370\u2013398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1128\/JCM.41.3.1277-1279.2003","article-title":"Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e Antigen-positive patients","volume":"41","author":"Chan","year":"2003","journal-title":"J. Clin. Microbiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"11630","DOI":"10.3748\/wjg.v20.i33.11630","article-title":"Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis","volume":"20","author":"Tarocchi","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jama.2013.276701","article-title":"Thirty-year outcomes of the national hepatitis B immunization program in Taiwan","volume":"310","author":"Chiang","year":"2013","journal-title":"JAMA"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/liv.13142","article-title":"Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: A systematic review and meta-analysis","volume":"36","author":"Raffetti","year":"2016","journal-title":"Liver Int."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.jhep.2020.01.007","article-title":"Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B","volume":"72","author":"Papatheodoridis","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/apt.14683","article-title":"Review article: The prevention of hepatitis B-related hepatocellular carcinoma","volume":"48","author":"Lin","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/apt.15499","article-title":"Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis","volume":"50","author":"Liu","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/jgh.15078","article-title":"Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review","volume":"35","author":"Tseng","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1001\/jamaoncol.2019.0650","article-title":"Risk of Hepatocellular Carcinoma in Patients Treated with Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study","volume":"5","author":"Choi","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/jgh.15783","article-title":"Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: An updated meta-analysis","volume":"37","author":"Yuan","year":"2022","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jhep.2022.12.007","article-title":"Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir-vs. entecavir-based regimens: Individual patient data meta-analysis","volume":"78","author":"Choi","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/apt.16197","article-title":"on the behalf of the ANRS\/AFEF study group. Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF\/ANRS CO22 Hepather cohort","volume":"53","author":"Pol","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2020.05.042","article-title":"Occult hepatitis B infection and hepatocellular carcinoma: Epidemiology, virology, hepatocarcinogenesis and clinical significance","volume":"73","author":"Mak","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2019.03.034","article-title":"Update of the statements on biology and clinical impact of occult hepatitis B virus infection","volume":"71","author":"Raimondo","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.gastro.2003.10.048","article-title":"Hepatitis B Virus Maintains Its Pro-oncogenic Properties in the Case of Occult HBV Infection","volume":"126","author":"Pollicino","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2893.2009.01085.x","article-title":"Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: A cohort study","volume":"16","author":"Ikeda","year":"2009","journal-title":"J. Viral Hepat."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"95","DOI":"10.14309\/ajg.0000000000001994","article-title":"Isolated Hepatitis B Core Antibody Positivity and Long-Term Liver-Related Mortality in Korea: A Cohort Study","volume":"118","author":"Sohn","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/jvh.13577","article-title":"Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A systematic review and meta-analysis of longitudinal studies","volume":"28","author":"Kamal","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1055\/s-0032-1323628","article-title":"Clinical features of hepatitis D","volume":"32","author":"Farci","year":"2012","journal-title":"Semin. Liver Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jhepr.2019.05.001","article-title":"The Oncogenic Role of Hepatitis Delta Virus in Hepatocellular Carcinoma","volume":"1","author":"Villanueva","year":"2019","journal-title":"JHEP Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2006.10.038","article-title":"Large Hepatitis Delta Antigen Modulates Transforming Growth Factor-b Signaling Cascades: Implication of Hepatitis Delta Virus\u2013Induced Liver Fibrosis","volume":"132","author":"Choi","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1139\/bcb-2017-0321","article-title":"Small Hepatitis Delta Antigen Selectively Binds to Target mRNA in Hepatic Cells: A Potential Mechanism by Which Hepatitis D Virus Downregulates Glutathione S-Transferase P1 and Induces Liver Injury and Hepatocarcinogenesis","volume":"97","author":"Chen","year":"2019","journal-title":"Biochem. Cell Biol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1158\/1541-7786.MCR-18-0012","article-title":"Molecular Signature and Mechanisms of Hepatitis D Virus-Associated Hepatocellular Carcinoma","volume":"16","author":"Diaz","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jhep.2010.06.008","article-title":"Outcome of chronic delta hepatitis in Italy: A long-term cohort study","volume":"53","author":"Niro","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1053\/j.gastro.2009.01.052","article-title":"A 28-year study of the course of hepatitis Delta infection: A risk factor for cirrhosis and hepatocellular carcinoma","volume":"136","author":"Romeo","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.46.3.420","article-title":"Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep)","volume":"46","author":"Fattovich","year":"2000","journal-title":"Gut"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2020.02.030","article-title":"Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies","volume":"73","author":"Alfaiate","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/apt.15188","article-title":"Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir","volume":"49","author":"Brancaccio","year":"2019","journal-title":"Aliment. Pharmacol. Ther."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/8\/1505\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:28:08Z","timestamp":1760106488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/8\/1505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":90,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["cancers16081505"],"URL":"https:\/\/doi.org\/10.3390\/cancers16081505","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]}}}